Mirador Therapeutics
William Sandborn is currently the Chief Strategy Officer at Mirador Therapeutics and a Member of the Board of Directors at Prometheus Laboratories Inc. With a background in medicine and experience in various leadership roles within the biosciences industry, William has a wealth of knowledge and expertise. Sandborn has co-founded multiple companies and played key roles in their acquisitions, including the $10.8 billion acquisition of Prometheus Biosciences by Merck in 2023. Their career has been marked by a commitment to advancing gastroenterology and hepatology, with previous roles such as Distinguished Professor of Medicine at the University of California, San Diego and Professor of Medicine at the Mayo Clinic.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.